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Abstract: Stem cell-based cardiac therapies have been extensively studied in recent years. However,
the efficacy of cell delivery, engraftment, and differentiation post-transplant remain continuous
challenges and represent opportunities to further refine our current strategies. Despite limited
long-term cardiac retention, stem cell treatment leads to sustained cardiac benefit following my-
ocardial infarction (MI). This review summarizes the current knowledge on stem cell based cardiac
immunomodulation by highlighting the cellular and molecular mechanisms of different immune
responses to mesenchymal stem cells (MSCs) and their secretory factors. This review also addresses
the clinical evidence in the field.
Keywords: mesenchymal stem cells; stem cell therapy; myocardial infarction; inflammation; heart failure
1. Introduction
Advanced cardiac support, medical therapy and early reperfusion strategies have
dramatically improved the survival rate in patients suffering from acute myocardial in-
farction (MI) [1]. Despite this success, the risk of heart failure (HF) following myocardial
infarction remains high in these patients, and there are no effective treatments available
to prevent this progression [2,3]. MI causes the loss of up to 1 billion cardiomyocytes [4].
Since the myocardium has negligible endogenous regenerative capacity, the significant
loss of cardiomyocytes ultimately leads to formation of scar, altered cardiac structure, and
compromised cardiac function. Development of HF following MI is closely associated with
adverse cardiac remodeling, a process linked to worsening cardiac function and chamber
dilatation [5]. While the extent of initial insult correlates with the level of post-MI remod-
eling, it is also highly dependent on the systemic immune response and ensuing cardiac
inflammatory response [2,3]. In fact, the inflammatory response after MI dictates the degree
of cardiac recovery. Inflammation, orchestrated by immune cells, is responsible for clearing
dead cells and matrix debris at the injury site. This process is vital to subsequent tissue
repair as it provides key molecular signals for activation of reparative processes. However,
prolonged tissue inflammation and infiltration of pro-inflammatory cells in the post-MI
myocardium exacerbates damage [6].
Cardiac repair is tightly coupled with the post-injury inflammatory process, which
suggests that targeting inflammation may hold promise in preserving cardiac tissue and re-
ducing mortality in patients surviving MI. Modulating the post-MI inflammatory response
as a therapeutic intervention is supported by seminal observations of biological processes
and cellular responses to tissue injury. As Huang et al. point out, modulating inflamma-
tion during the early phase post-MI prevents infarct expansion by reducing border zone
cardiomyocyte (CM) injury and necrosis [7]. Attenuation of excessive and prolonged pro-
inflammatory signaling may also protect cardiomyocytes during the cardiac remodeling
phase by reducing apoptosis. In addition, modulation of the post-MI immune response
could promote a healing microenvironment and reduce scar formation as the signaling
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pathways between inflammation, protease activation, and fibrogenic signaling are exten-
sively connected. Lastly, selective activation of the immune signaling pathway could alter
cell recruitment into the area of infarction. However, clinical studies on broad immunosup-
pressive agents for post-MI heart failure or other cardiac diseases do not improve cardiac
healing [8,9]. Glucocorticosteroids and non-steroidal anti-inflammatory therapeutics are
associated with higher mortality and recurrent MI [10,11], while studies aiming to deplete
inflammatory cells fail to demonstrate benefit [12]. Therefore, strategies that modulate
immune cells and their secretome after MI, rather than a complete inflammation blockade,
may provide better therapeutic strategies.
Among the various immune cells involved in the post-MI immune response, neu-
trophils and macrophages play key role in the healing process. Neutrophils are the first im-
mune cells to arrive at the injured myocardium and play an important role in the clearance
of dead cells, in addition to setting the intensity of the subsequent inflammatory response.
Macrophages also play an important role in the early inflammatory and subsequent repara-
tive phases. They are generally classified into pro-inflammatory/classically activated/M1-
like and anti-inflammatory/alternatively activated/reparative/M2-like macrophages based
on gene profile and function [13,14]. Pro-inflammatory macrophages dominate the early
phase after MI (1–5 days), while anti-inflammatory macrophages are in the majority in
the later healing phase, promoting tissue healing and angiogenesis [15]. There is a grow-
ing body of evidence that suggests that alternative macrophage polarization to an anti-
inflammatory phenotype protects against the early development of ischemic damage and
subsequent adverse cardiac remodeling [16,17]. Given the complexity of immune signaling
cascades and their interconnected biological functions, current approaches are refined to
focus on targeting the distinct regulatory mechanisms that can direct specific immune cell
populations to promote cardiac repair.
2. Stem Cells as Cardiac Immunomodulatory Therapy
Adult stem cell based cardiac therapies have been investigated in clinical trials with the
rationale that they could repopulate and regrow/repair the lost/injured cardiac tissue [18].
However, the results from multiple studies indicate that transplanted adult stem cells do not
directly replace the lost myocardium, they do not differentiate into cardiomyocytes. Instead,
recent reports suggest that the observed cardiac functional improvement is associated with
stem cell-mediated reparative mechanisms and immunomodulatory functions within the
infarcted myocardium [19]. In-depth mechanistic studies further reveal that the stem cell
secretome is enriched in various growth factors, cytokines, microRNAs, and exosomes
that modify surrounding cells and the microenvironment. Increasing evidence suggests
that stem cells orchestrate a pro-regenerative microenvironment in post infarcted tissue
by modulation of specific immune pathways and cell populations. Among the stem cell
types in the literature, bone marrow derived mesenchymal stem/stromal cells (MSCs) and
cardiosphere-derived cells (CDCs) are most widely studied [20].
2.1. Immunoregulatory Function of Mesenchymal Stem/Stromal Cells (MSCs)
MSCs represent a multi-potent population is extensively investigated as cell therapy
for multiple diseases due to their accessibility. MSCs are harvested from various adult
tissues such as bone marrow, adipose tissue, connective tissues, and umbilical cord [21].
Unlike hematopoietic stem cells, MSCs are characterized by the presence of certain criteria
including: (1) their ability to adhere to plastic culture plates under standard culture
conditions; (2) the expression of CD105, CD73, CD44, and CD90 among others; (3) the
lack of CD45 or CD11b expression; and (3) their ability to differentiate into osteoblasts,
adipocytes, and chondroblasts in vitro [21].
While MSCs were initially examined in cardiac applications due to their capacity
to differentiate into different cell types, It was later found that MSCs produce abundant
paracrine factors including soluble growth factors, cytokines, and exosomes that mediate
wound healing [21]. In addition, these secretory factors modulate the immune system both
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locally and systemically [22]. Together, these characteristics make MSCs a particularly
attractive therapeutic cell type for post-MI cardiac applications. MSCs modulate inflamma-
tion by shifting leukocyte function and phenotypes via both direct cell contact and through
soluble factors [23,24]. Different studies show that MSCs modulate neutrophil activity,
regulate T-cell proliferation, and influence macrophage polarization. Here we focus on the
multifaceted roles of MSCs in modulating immune cells in the context of cardiac injury.
2.1.1. Immunoregulatory Effects of MSCs on Neutrophils
Following MI, damage-associated molecular patterns (DAMPs) activate tissue-resident
cells to release pro-inflammatory cytokines and chemokines. This attracts a massive infiltra-
tion of the earliest immune cells to arrive in the myocardium after MI, neutrophils, to the
cardiac tissue and initiates the deleterious inflammatory response [25]. In response to tissue
injury, neutrophils undergo an oxidative response that triggers neutrophil extracellular
trap (NETs) formation, neutrophil apoptosis and reactive oxygen species (ROS) production.
Research shows that MSCs can suppress neutrophil activation and attenuate neutrophil
mediated tissue injury by altering neutrophil oxidative metabolism [26,27]. Jiang et al.,
report that MSCs suppress the formation of NETs and the release of neutrophil death re-
lated protease by upregulating extracellular superoxide dismutase 3 (SOD3) in vivo [26]. In
addition, IL-6 secretion from MSCs significantly inhibits neutrophil apoptosis in vitro [28].
Interestingly, this anti-apoptotic MSC activity does not require cell-to-cell contact, as the
cells cultured in trans-well experiments still produce this effect. Further research shows
that MSCs have no effect on neutrophil phagocytosis, expression of adhesion molecules, or
chemotaxis [29].
2.1.2. Immunoregulatory Effects of MSCs on Macrophage
Since macrophages are key mediators of immune response, the effects of MSCs on
macrophage populations after cardiac injury are well documented in many studies and
represent a critical step in MSC-mediated cardiac protection [30]. In co-culture experiments,
MSCs reduce macrophage production of key pro-inflammatory cytokines such as TNFα,
IL-1β, IL-6, IFNγ, and IL-12; while simultaneously increasing anti-inflammatory cytokine
expression [31]. MSC secretomes enriched with Prostaglandin E2 (PGE2), IL-1Rα, and
TGFβ, are known to facilitate M1 to M2 macrophage polarization [32], In addition, MSCs
recruit macrophages to the infarct site and induce M2 macrophage polarization through
the release of IL-10, indoleamine 2,3-dioxygenase (IDO), C-C motif ligand 18 (CCL18)
and PGE2 [33,34]. Interestingly, pro-inflammatory factors such as IFNγ, TNFα and LPS
further enhance MSC-mediated M2 macrophage polarization by enhancing MSC produc-
tion of PGE2, indoleamine 2,3-dioxygenase (IDO), and cyclo-oxygenase 2 (COX2) [35].
Macrophages play a key role in cardiac recovery post-MI as their phenotypes and secre-
tomes closely govern multiple aspects of tissue recovery after injury [36]. By polarizing
macrophages to an anti-inflammatory phenotype early after injury, MSCs may prevent a
maladaptive immune response and contribute to multiple aspects of cardiac recovery.
2.1.3. Immunoregulatory Effects of MSCs on Lymphocytes
The interaction between MSCs and lymphocytes is an active area of research. Stud-
ies show that MSCs have direct and indirect effects on the activation and proliferative
state of lymphocytes. One proposed mediator of this phenomenon is an antagonist of
IL1 receptor (IL1RA) secreted by MSCs. Luz-Crawford et al. report that MSC secreted
IL1RA acts on both macrophages, by inducing a polarization toward the anti-inflammatory
M2 phenotype; and on B-lymphocytes, by reducing plasmablast formation [37]. This is
important in the context of MI since B-lymphocytes trigger monocyte mobilization and
impair heart functional recovery after MI [38]. Moreover, B cells produce antibodies that
interfere with cardiomyocyte function and are elevated in heart failure [39]. Although
detailed mechanisms are still lacking, evidence suggests that MSC-derived CCL2 inhibits
STAT3 activation in plasma cells, leading to attenuated immunoglobulin production [40].
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Therefore, the data suggest an important and critical role for MSCs in modulating the
function of lymphocytes following cardiac ischemic injury.
There is also considerable evidence to support MSC mediated T-cell modulation. A
murine study utilizing CD4+ T cell-deficient mice resulted in significantly smaller infarct
sizes compared with wild type controls This study is the first evidence that CD4+ T cells
contribute to myocardial ischemia-reperfusion injury [41]. Thus, regulatory mechanisms
that prevent T cell expansion after MI can directly reduce the production and infiltration of
pro-inflammatory T cell populations and prevent excessive myocardial injury. Reports have
identified that cell-to-cell interaction between MSCs and T cells promotes T cell apoptosis
via co-inhibitory surface ligands, Fas ligand (FasL) and TNF-Related Apoptosis-Inducing
Ligand (TRAIL) [42,43]. In addition, MSC secretomes enriched in inducible NO synthase
(iNOS), IDO, TGFβ, and PGE2 mediate the phenotype, proliferation, and activation state
of T cell populations without direct cell contact [27,42]. Furthermore, MSCs enhance the
immunosuppressive capabilities of FOXP3+ T-regulatory cell populations, which further
limits pro-inflammatory T cell proliferation [44], which is believed to be mediated by TGFβ
and PGE2 enriched MSC secretome.
2.2. Immunomodulatory Properties of Cardiosphere-Derived Cells (CDCs)
Cardiosphere-derived cells (CDCs) are a cardiac-derived progenitor cell population
that resemble the phenotype of MSCs and can be expanded ex vivo from cardiac tissue
biopsies. There are multiple studies that examined resident cardiac progenitor cells such
as cKit+ and Sca1+ cell populations. These studies reached similar conclusions and indi-
cated that the contribution of these cells to adult myocardial repair and homeostasis is
limited [18,45,46]. However, this methodology has been challenged by other investigators
and this topic remains controversial [47,48]. Nonetheless, the consensus in the field is
that the minimal intrinsic repair and homeostasis observed in adult mammalian heart is
related to negligible proliferation of existing cardiomyocytes. Recent evidence has sug-
gested a link between CDCs and the development if atrial myxomas [49], however, it is
important to note that these observation has not been replicated in clinical studies that
transplanted CSCs in multiple clinical scenarios. Studies show that CDCs possess stem cell
properties including clonogenicity and multilineage differentiation, and have been shown
to enhance cardiac repair in preclinical models [50]. In clinical trials, autologous CDCs
have been proven safe for treating patients with MI [51,52]. Early research proposed that
CDC-mediated cardiac repair mechanisms include direct differentiation and contribution
to new myocardium, however, limited engraftment of injected cells suggests that paracrine
effect is likely responsible for the majority of the observed therapeutic benefits [53].
Similar to MSCs, allogenic CDCs are reported to exert immunomodulatory effects. In
a co-culture system, Dutton et al. show that MHC-mismatched CDCs suppress lymphocyte
proliferation and activation in response to Concanavalin A [54]. The authors report that
CDC mediated inhibition of lymphocyte proliferation is partially facilitated by soluble
factors including high levels of PGE2, which leads to down-regulation of lymphocyte CD25
expression via the EP4 receptor. In the setting of MI, CDC secreted PGE2 can have a direct
reparative effect by modulating cardiac inflammation.
Another major component of the CDC secretome includes exosomes, which reportedly
mediate macrophage polarization [55]. Intracoronary injection of CDC derived exosomes
(EV-CDCs) results in an increase of M2-like macrophages with lower pro-inflammatory
gene expression [56]. Additional mechanistic studies demonstrate that EV-CDC-derived
exosomes are enriched in regulatory peptides and miRNAs related to immune and cardiac
function regulation [57]. Cambier et al. reported that EV-CDCs contain high levels of
a Y RNA fragment (YF1) which induces macrophage IL-10 production. YF1 primed
macrophages are also cytoprotective for CMs and in vitro reduce the detrimental effects of
oxidative stress through secreting IL-10. Intracoronary administration of EV-YF1 following
ischemia/reperfusion in rats reduces infarct size. In vivo studies in rats and pigs using
EV-CDCs also show a reduction of infiltrating macrophages in the infarcted tissue. These
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observed changes are linked to EV-CDC mediated alternative macrophage polarization
through miRNAs, such as mir-181b [58].
3. MSC Therapy in Clinical Trials
Various types of stem cells are utilized to enhance myocardial function in ischemic
heart disease (IHD), yet the optimal cell type for cardiac repair is unknown. There are two
main mechanisms attributed to stem cell-based therapies: the widely accepted paracrine
mechanism through which cells release a myriad of growth factors that activate endogenous
pathways, eventually aiding the ailing cardiac muscle; and the less proven theory of trans-
differentiation into cardiac cells [59]. Mesenchymal stem cells (MSCs) emerge as a leading
candidate for cardiac applications and exert the majority of their beneficial effects through
paracrine pathways [60]. This part of the review focuses on the clinical applications of cell
therapies in IHD with a particular focus on MSCs (Tables 1 and 2).
3.1. Acute Myocardial Infarction (AMI)
Autologous bone marrow mononuclear stem cells (BMMNCs) are the most clini-
cally utilized cell type for ischemic heart disease. Autologous BMMNCs offer multiple
advantages including minimal ex-vivo processing, easy accessibility, and reduced immuno-
genicity. Initial results were promising, however, more careful examination of their benefits
in recent trials demonstrates little improvement in cardiac function compared to standard
therapy. Large-scale, randomized, placebo-controlled trials show only minor benefits, as
confirmed by a meta-analysis published in 2015 [61,62]. In addition, the phase III BAMI
trial announced in 2020, suffered slow enrollment and failed to demonstrate mortality
benefit with BMMNCs [63].
Bone marrow mesenchymal stem cells (BMMSCs), on the other hand, fare better in
animal and human studies. MSCs are rare and pluripotent cells that represent only 0.01%
of total BMMNCs and can differentiate into a variety of mesoderm lines such as adipocytes,
chondrocytes, and bone cells [64]. In 2004, Chen et al. report the first randomized trial
to deliver autologous MSCs to post-AMI patients via intracoronary injection. Six months
following therapy, the LVEF in the MSC group demonstrate significant improvement
compared to standard therapy. This study also establishes the safety of autologous MSCs
for cardiac applications [65]. Subsequently, Hare et al. report the safety and efficacy of
intravenous administration of allogeneic MSCs in a post-primary percutaneous coronary
intervention (PCI) AMI population. Similar to intracoronary administration, intravenous
MSCs result in enhanced LVEF recovery and no side effects [66]. The beneficial effects
of MSCs and their safety are confirmed in a study by Lee et al. who randomize 58 AMI
patients to receive MSCs or placebo [67].
Adipose tissue-derived mesenchymal stem cells (ADMSCs) share many biological
properties with BMMSCs and hence gathered interest for their use in cardiac applica-
tions [68]. In fact, the frequency of colony formation in ADMSCs exceeds that of BM and
cord blood (CB) derived MSCs. This makes them an attractive target for tissue regenera-
tion applications, since ADMSCs are expected to have the same therapeutic potential as
BMMSCs but are more easily and safely collected [69]. In the APOLLO trial, Vulliet and
colleagues randomize 14 patients with AMI to receive intracoronary infusion of ADMSCs
or placebo and patients are followed for 6 months, after which cardiac perfusion and scar
formation are assessed using single-photon emission computed tomography (SPECT). The
study shows similar benefits to those observed with BMMSCs in enhancement of cardiac
tissue perfusion and reductions in scar size [70].
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Table 1. Human studies of the cardiac applications of mesenchymal stem cells.
Study Name Year Disease Study Type Cell Type n Follow Up Results
AMI
Chen et al. [71] 2004 AMI Randomized,PC
Autologous
BMMSCs 69 6 m
Improved LVEF and
myocardial perfusion
Hare et al. [72] 2009 AMI Randomized,DB, PC
Allogeneic
BMMSCs 53 6 m
Improved LVEF and
symptoms
APOLLO [76] 2012 AMI Randomized,DB, PC Autologous ADSCs 14 6 m
Improved perfusion and scar
formation
Lee et al. [73] 2014 AMI Randomized,No PC
Autologous
BMMSCs 58 6 m Improved LVEF
Gao et al. [78] 2015 STEMI Randomized,DB, PC UC-MSCs 116 18 m
Improved LVEF, LV volumes,
perfusion
Chronic HFrEF









6 mw and reduced infarct size
Allogenic MSCs-improved










Improved LVEF, LVESV, and
symptomsNYHA 2
or 3



















BMMSCs 30 12 m
No significant difference
between treatments
PRECISE [83] 2014 ICM withNYHA 2-3
Randomized,
DB, PC Autologous ADSCs 27 36 m
Preserved MVO2, improved
LV mass and wall motion
score index












Improved LVEF and LV
volumes, symptomLVEF < 45




BMMSCs 60 3 y
Improved mortality and
HF-related MACE




BMMSCs 10 2 y

































vs. Allogenic: no significant
difference) and 6 min walk
test (Autologous better
than Allogenic).
TRIDENT [81] 2017 ICM Randomized,DB, PC
Allogeneic
BMMSCs 60 12 m
Improved infarct size,
symptom
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Table 1. Cont.







BMMNCs 46 12 m
UC-MSCs-improved EF, SV, 6
mw, and reduced infarct size
LVEF < 45 BMMNCs–reducedinfarct size
AMI: acute myocardial infarction, HFrEF: heart failure with reduced ejection fraction, STEMI: ST-elevation myocardial infarction, ICM:
ischemic cardiomyopathy, LVEF: left ventricular ejection fraction, NYHA: New York heart association functional classification, LVAD: left
ventricular assist device, CABG: Coronary artery bypass grafting, NIDCM: non-ischaemic dilated cardiomyopathy, PC: placebo control, DB:
double blind, SB: single blind, BMMSCs: bone marrow mesenchymal stem cells, ADSCs: adipose tissue derived stem cells, UC-MSCs:
Human umbilical cord-derived mesenchymal stem cells, BMMNCs: Bone marrow-derived mononuclear cells, LV volumes: left ventricular
volumes, 6 mw: 6 min walk test, LVEDV: left ventricular end-diastolic volume, MVO2: myocardial volume oxygen, HF-related MACE:
heart failure-related 3-major adverse cardiovascular events, SV: stroke volume.
MSCs from various compartments of the umbilical cord, such as veins, arteries, Whar-
ton’s jelly, and umbilical cord lining, accumulate in damaged tissue and promote tissue
repair. Umbilical cord- mesenchymal stem cells (UC-MSCs) have faster self-renewal ca-
pacity compared to BMMSCs and are less likely to form teratomas [71]. Gao et al. report
the efficacy of UC-MSCs in 116 patients with ST elevation myocardial infarction (STEMI).
UC-MSC treated patients have better cardiac functional recovery, ameliorated adverse
cardiac remodeling and enhanced cardiac perfusion as assessed by SPECT 18 months after
MI [72].
3.2. Chronic Heart Failure Reduced Ejection Fraction (Chronic HFrEF)
Multiple human studies examine MSC therapy in patients with chronic heart failure
with reduced EF (HFrEF) including ischemic cardiomyopathy (ICM), dilated cardiomy-
opathy (DCM) and non-ischemic cardiomyopathy (NICM) (summarized in Table 1). In the
POSEIDON trial, Hare et al. conduct a study comparing the safety and efficacy of allogeneic
vs. autologous MSCs in ICM patients. The study demonstrates the comparable efficacy and
safety of both approaches, yielding significant reduction in infarct size and improvement
in cardiac functional recovery. The safety of both cell strategies is confirmed with no side
effects attributed to either approach. However, in the autologous BMMSC-administered
group, 6-min walk test is significantly increased as compared with allogeneic BMMSCs [73].
In a follow-up study using allogeneic BMMSCs in patients with NIDCM, BMMSC-treated
patients experience smaller scar size and less heart failure symptoms at 12 months of
follow-up [74]. These studies and others in the literature confirm the safety of BMMSCs in
chronic HFrEF patients and suggest that allogeneic MSCs may be used as an alternative to
autologous MSCs. However, these clinical trials generally enroll small numbers of study
subjects and some of them lack a placebo arm, hence, future large randomized studies are
needed to advance the field forward.
Several studies compare the effectiveness of BMMNCs and MSCs. The TAC-HFT trial
(2014) is a phase I/II study of BMMNCs vs. BMMSCs or placebo in ICM patients with
LVEF <50%. Patients with MSC treatment show significant improvements in symptoms,
infarct size, and regional as well as global myocardial function [75]. These results suggest
the benefit of using selected populations of BM cells for cardiac applications. In 2014,
Ascheim et al. report a randomized clinical trial comparing allogeneic MSCs to placebo in
advanced heart failure patients requiring left ventricular assist device (LVAD) support [76].
They report no clear advantage to MSC administration, although MSC-treated patients
experience more successful LVAD weaning and longer duration off LVAD support. These
results are replicated in multiple small clinical trials, which supports the clinical benefit of
MSCs in comparison to standard care alone in cardiomyopathy patients in terms of both
LVEF improvement and symptom reduction [77–81].
Preconditioning MSCs prior to transplantation incorporates the use of specific growth
factors to enhance their cardioprotective effects, engraftment or survival after transplan-
tation. The cardiogenic stem cell therapy (C-CURE) trial tests the utility of cardiogenic
cocktails to enhance the therapeutic benefit of MSCs, including TGFβ, BMP4, activin-A,
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retinoic acid, FGF2, IGF1, alpha-thrombin, and IL-6, in addition to 5% platelet lysate at the
onset of a 5-day incubation period. This plan was to induce cardiac transcription factor
expression, potentiate nuclear translocation, and maintain cell cycle progression in an
attempt to enhance the therapeutic effect of autologous MSCs for cardiac regeneration in
ICM patients [82]. While they identify no adverse events with preconditioned autologous
BMMSCs and report significant improvement in global left ventricular function, reduced
adverse remodeling and increased 6-min walk test at 2 years follow-up, it is important
to note that the C-CURE trial is a small clinical study which does not include a placebo
arm. Bartunek et al. confirm the safety and efficacy of cardiac preconditioned autologous
BMMSCs [84]. In CHART-1 trial, 271 patients with ischemic cardiomyopathy are ran-
domized to receive either intracranial delivery of autologous cardiogenic preconditioned
BMMSCs or sham procedure. The primary outcomes (all-cause mortality, worsening heart
failure events, Minnesota Living with Heart Failure Questionnaire (MLHFQ), 6-min walk
distance, LVEF and left ventricular end systolic volume (LVESV)) were similar between
both groups. However, cell therapy improves 6-min walk distance in the subgroup of
patients with baseline left ventricular end-diastolic volume (LVEDV) of 200–370 mL (60%
of patients), which suggests a differential therapeutic response based on the degree of
underlying cardiac dysfunction. While LVEDV was used to stratify cardiac dysfunction
in the CHART-1 trial, other cardiac functional indices may further stratify patients and
identify those with the highest likelihood of therapeutic benefit.
In addition to studies that focus on BMMSCs, Perin et al. examine the therapeutic
utility of ADMSCs in ICM patients [83]. 27 patients with ICM are randomized to either
ADMSCs or placebo and followed for 36 months. The change in exercise capacity from
baseline to 6 and 18 months is significantly ENHANCED in ADMSC-treated patients com-
pared with controls. In addition, ADMSC-treated patients show significant improvement
in total left ventricular mass by magnetic resonance imaging and wall motion score index.
The RIMECARD trial examines the efficacy of UC-MSCs in HFrEF patients [85]. UC-
MSC-treated patients show no adverse events related to the cell infusion and none of the
patients develop alloantibodies to the UC-MSCs. Furthermore, UC-MSC-treated patients
exhibit significant improvement in LVEF. In addition, the recently reported HUC-HEART
trial compares the effects of UC-MSCs and BMMNCs in ICM patients [86]. UC-MSCs
improve global cardiac function, stroke volume, and 6-min walk distance at 12-month
follow-up. Improvements in infarct size are observed in both UC-MSC and BMMNC
treated arms, but the improvement is greater in UC-MSC-treated patients.
These results suggest a high degree of safety of MSC therapy in patients with acute
MI and chronic HFrEF including ICM and NIDCM. The efficacy of MSC therapy in human
studies is consistent, yet minimal, and efforts are needed to further refine the therapy
and its timing to uncover the full potential of this therapeutic. The phase 3 DREAM-HF
trial of randomized allogeneic MSCs to 566 patients with chronic HF due to LV systolic
dysfunction of either ischemic or nonischemic etiology is underway and these results may
help identify patients and clinical scenarios where MSC therapy will be most beneficial [87].
Table 2. Human studies of the cardiac applications of cardiosphere derived stem cells.
Study Name Year Disease Study Type Cell Type n Follow Up Results
CADUCEUS [51,52] 2014 ICM Randomized,No PC
Autologous
CDCs 25 1 y
Improved scar size, viable heart mass,
regional contractility, regional systolic
wall thickening
DYNAMIC [88] 2020 HFrEF NoRandomized
Allogeneic
CDCs 14 1 y Improved LVEF, QOL
ALLSTAR [89] 2020 ICM Randomized,DB, PC,
Allogeneic
CDCs 134 6 m
Improved LVEDV, LVESV, decreased
plasma BNP
ICM: ischemic cardiomyopathy, HFrEF: heart failure with reduced ejection fraction, PC: positive control, DB: double blind, CDCs:
cardiosphere-derived cells, LVEF: left ventricular ejection fraction, QOL: quality of life, LVEDV: left ventricular end-diastolic volume,
LVESV: left ventricular end-systolic volume.
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4. Cardiosphere Derived Stem Cells (CDCs)
CDCs are extracted and isolated from the patient’s own myocardium providing an
excellent source of autologous stem cells for cardiac applications. After early success in
animal models, multiple clinical trials demonstrate the safety and efficacy of autologous
CDC therapy in humans (summarized in Table 2). In the CADUCEUS trial, enrolling 25 pa-
tients (17 in CDC group and 8 in standard of care alone group) 2–4 weeks after myocardial
infarction with LVEF 25–45%, autologous CDCs are infused into the infarct-related artery
1.5–3 months after myocardial infarction [51,52]. CDC therapy is safe and associated with
significant reduction in scar mass as well as increases in viable cardiac mass, regional
contractility, and regional systolic wall thickening. However, these positive changes do
not result in significant improvement in LVEF and LVEDV at 6 months. The DYNAMIC
trial, enrolling 14 patients with dilated cardiomyopathy (ischemic and nonischemic) with
an EF < 35% and NNYHA class III/IV, delivers four escalating doses of allogenic CDCs by
sequential non-occlusive technique to all three major coronary arteries [88]. No primary
safety endpoints are observed, confirming the safety of therapy. Compared to baseline
there is an improvement in EF, LVESV, quality of life (QOL) questionnaires and NYHA
class at 6 months post therapy.
The second generation of CDC trials is larger and conducts more comprehensive
studies. ALLSTAR trial enrolls 134 patients (90 to the CDC group and 44 to the placebo
group), 4 weeks to 12 months after MI, with left ventricular ejection fraction (LVEF) ≤ 45%
and LV scar size ≥15% of LV mass by cardiac MRI [89]. Allogenic CDCs are infused into
the infarct-related artery. Intracoronary delivery of allogeneic CDCs is safe but is not
associated with a reduction in LV scar size, the primary endpoint. The trial is subsequently
discontinued due to the low probability of detecting a significant treatment effect of CDCs
based on the primary endpoint. However, infusion of CDCs appears to have a modest
favorable impact on LV remodeling, with halted increases in LVESV and LVEDV relative
to placebo at 6 months. Additionally, there is a greater reduction in NT-proBNP values at
6 months in CDC-treated patients.
The difference between the two major CDC human trials is interesting. The CA-
DUCEUS trial shows an improvement in scar size but the ALLSTAR trial does not confirm
this finding. While the CADUCEUS trial demonstrates 7.7% reduction in scar size at
6 months with autologous CDC infusion and 0.3% reduction in scar size in controls [51], the
ALLSTAR trial demonstrates a 5.0% reduction in scar size at 6 months with allogenic CDC
and 4.1% reduction in scar size in controls [89]. The difference between these two trials is
due to change in scar size in the control group in the latter study. This difference may be
related to the patient population enrolled and recent advances in standard of care therapy.
5. Future Perspectives
Cardiac repair is a complex process with dynamic changes in tissue composition and
cellular populations at play. Stem cell therapy offers a promising clinical treatment option
to modulate post-injury inflammation and enhance cardiac recovery in a multitude of
acute and chronic cardiac conditions. Early studies of cardiac cell therapy utilizing MSCs
and CDCs successfully demonstrated their clinical safety and efficacy while highlighting
important challenges that need to be addressed as the field continues to move forward.
First, in order to refine and maximize the benefits of stem cell based cardiac therapy,
there is real need for improving our understanding of the biology behind MSC- and CDC-
mediated immunomodulation. It has been shown that tissue source, culture conditions,
isolation methods, and cell preservation methods influence MSC phenotype and secretory
function [90,91]. Lack of standardized MSC isolation and culture protocols also complicate
the evaluation of MSC based treatments [92]. Moving forward, it is particularly important
to compare these methodologies and stanbdardize them for future cardiac regeneration
studies. In addition, rigorous studies comparing MSCs-derived cellular products with
intact MSCs are needed as recent evidence suggest that apoptotic, metabolically inactivated,
or fragmented MSCs still possess immunomodulatory capabilities [93,94]. This approach
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provides valuable alternative to live MSC treatment, as cell fragments or byproducts carry
reduced tumorigenic or cellular rejection concerns.
Second, an important part of cardiac cell-based therapies depends on their reten-
tion and ability to survive in the heart following transplantation. The incorporation of
biomaterials such as biocompatible scaffolds are presently being investigated in animal
models to enhance the survival of transplanted cells. Future studies focused on developing
biodegradable and biocompatible scaffold materials with refined encapsulation methods
are likely to enhance the efficacy of cell-based therapy while reducing the need for large
number of transplanted cells.
Third, aging is one of the most significant risk factors in cardiovascular disease. While
studies report that CDCs and MSCs are beneficial in young animal, there is limited evidence
on whether these therapies improve aging related cardiac functional decline [95]. Since
aging also affects the immune system at multiple levels, future studies need to address
whether stem cell mediated immunomodulation slows the progression of age-related
cardiac decline.
Lastly, the synergy of combining different progenitor cell types with complementary
properties might lead to enhanced cardiac repair. For instance, since cardiac damage
does not lead to the generation of new cardiomyocytes (CMs), induced pluripotent stem
cells (iPSCs) derived CMs (iPSC-CMs) are an attractive therapeutic approach to replace
lost cardiac muscle. New strategies combining three-dimensional (3D) cardiac organoids
(CO) with iPSC-CMs show enhanced CM maturation over conventional two-dimensional
(2D) culture systems [96]. Advances in this area offers an opportunity to transplant an
organized mini-organ/tissue incorporating stem cells, vascular cells, and iPSC-CMs in a
defined micro-anatomy. In addition to direct transplantation, COs offer the opportunity to
personalize drug screening and disease modeling in vitro. However, no rigorous clinical
studies on CO transplantation in humans are performed to date.
6. Conclusions
The very limited cardiac recovery capacity of the adult heart drives a large effort in re-
cent decades to facilitate myocardial repair. MSCs and CDCs hold the therapeutic potential
to orchestrate balanced cardiac healing by recruitment of immune cells to the injury site for
necessary matrix remodeling and removal of dead cells while simultaneously modulating
their phenotype to enhance tissue recovery and promote wound healing. While there is no
clear evidence of trans-differentiation of transplanted cells into new cardiomyocytes, there
is clear evidence of paracrine activity. Advancements in identification and isolation of spe-
cific stem cell paracrine factors that promote healing and reduce unchecked inflammation
will lead to subsequent refinement of stem cell-based therapies, which remain a promising
treatment for acute MI patients and other cardiovascular diseases. Future generations of
refined stem cell-based therapies remain a promising treatment for acute MI patients.
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